Revelation Biosciences (REVB) CEO Rolke gave up 10,115 shares at $1.13 to cover taxes or an exercise price
Insider transactions reported
James Rolke (Chief Executive Officer at Revelation Biosciences Inc., REVB) reported that they gave up 10,115 shares at $1.13 to cover taxes or an exercise price on Apr 30, 2026. After these transactions the filing shows 214,738 shares held directly.
- Reporting person
- Rolke James
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Shares withheld for taxes or exercise price (F) | Common Stock1, 2 | -10,115 | $1.13 | $11.4K | 214,738 direct |
Holdings before and after
- Common Stock: 224,853 to 214,738 direct
Footnotes from the filing
- 1. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction codes in this filing
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Rolke report in this REVB Form 4?
James Rolke (Chief Executive Officer at Revelation Biosciences Inc., REVB) reported that they gave up 10,115 shares at $1.13 to cover taxes or an exercise price on Apr 30, 2026. After these transactions the filing shows 214,738 shares held directly.
How many REVB shares does Rolke hold after this filing?
The filing shows 214,738 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code F mean on an SEC Form 4?
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
Historical context for REVB
Across the 15 sessions after earlier REVB headlines, the stock closed higher 3 times and lower 12 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | REVB | SPY |
|---|---|---|---|
| Apr 6, 2026 | Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | -7.2% | +0.5% |
| Mar 30, 2026 | Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study | +5.3% | -0.3% |
| Mar 24, 2026 | REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | -8.2% | -0.3% |
| Mar 19, 2026 | Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | -1.6% | -0.2% |
| Feb 27, 2026 | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | -0.8% | -0.5% |
| Jan 26, 2026 | Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | -14.9% | +0.5% |
Earlier insider filings at REVB
- May 1, 2026Chief Financial Officer Zygmont Chester Stanley Iii covered exercise/tax liability with 13,285 shares (SEC Form 4) to satisfy withholding tax
- Feb 5, 2026Director Roper Jess covered exercise/tax liability with 1,591 shares, decreasing direct ownership by 11% to 12,828 units (SEC Form 4)
- Feb 5, 2026Director Chawla Lakhmir S covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 16% to 12,158 units (SEC Form 4)
- Feb 5, 2026Director Carver Jennifer covered exercise/tax liability with 1,661 shares, decreasing direct ownership by 12% to 12,758 units (SEC Form 4)
- Feb 5, 2026Chief Executive Officer Rolke James covered exercise/tax liability with 8,521 shares, decreasing direct ownership by 4% to 224,853 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Follow REVB and get a push notification the moment its next story breaks.